U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07486700) titled 'The Phase I Study of SIG001 Antibody on Cancer Therapy.' on March 11.
Brief Summary: The goal of this clinical trial is to learn the safty characteristics of SIG001 Mab in cancer patients; It will also determine the Recommended Phase II dose of SIG001 Mab on cancer treatment, and pharmacological characteristics of SIG001. The main questions it aims to answer are:
What is the safety and tolerability of SIG001 in patients with advanced solid tumors ? What is the Recommended Phase II dose of SIG001? What is the PK/PD characteristics of SIG001 in cancer patients? What is the antitumor activity of SIG001 in cancer patients? What is the...